Heliospectra reported high sales growth in Q3 as expected. However, the company needs to continue increasing the average order size while also improving its gross margin to reach break-even. We see great potential for larger orders during the coming year, especially from the medical plants segment which is expected to flourish following the legalization of cannabis in Canada.